Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1
December 13, 2024 | 07:00
Transcenta Holding Limited, announced late-breaking presentation of preclinical study results of novel humanized LIV-1 antibody based ADCs at 2024 San Antonio Breast Cancer Symposium (SABCS).
Mobile Version